{"id":3738,"date":"2026-11-17T15:01:42","date_gmt":"2026-11-17T15:01:42","guid":{"rendered":"https:\/\/indiamedicine.org\/?p=3738"},"modified":"2026-11-17T15:01:42","modified_gmt":"2026-11-17T15:01:42","slug":"how-india-trains-drug-inspectors-who-fellowship-gmp-checks","status":"publish","type":"post","link":"https:\/\/indiamedicine.org\/?p=3738","title":{"rendered":"How India Trains Drug Inspectors: WHO Fellowship &#038; GMP Checks"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Every certificate of WHO-GMP compliance, every import registration, and every <em>not of standard quality<\/em> alert that an international buyer relies on is produced by a human being: a drug inspector. The strength of India&#8217;s regulatory paperwork is therefore capped by the strength of its inspection workforce. In November 2026, that workforce came into focus with a quiet but consequential development \u2014 India will begin sending CDSCO drug inspectors to the World Health Organization&#8217;s headquarters in Geneva for a rotational fellowship, with the first posting expected to start in February 2027.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This guide explains how Indian drug inspectors are selected, trained and deployed, what the WHO rotational fellowship actually involves, and \u2014 most practically for buyers \u2014 how to read inspection-derived documents knowing where the capacity constraints sit.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f52c; Who Inspects a Pharmaceutical Plant in India<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A common misconception among international buyers is that the Central Drugs Standard Control Organisation (CDSCO) inspects Indian factories. In practice, the split is a federal one:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>State Drug Control Administrations<\/strong> license manufacturing establishments and conduct the routine manufacturing inspections, under the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945.<\/li>\n\n<li><strong>CDSCO<\/strong>, headed by the Drugs Controller General of India (DCGI), handles new drug approvals, clinical trial permissions, import registration, and central coordination \u2014 including joint inspections where quality concerns escalate.<\/li>\n\n<li><strong>Joint teams<\/strong> are formed when a complaint, an adverse event cluster, or an export rejection triggers a central-level look at a specific facility.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">That federal structure matters to buyers because inspection intensity varies by state. The same statutory standard is enforced by 28-plus different administrations with different staffing, budgets and laboratory access. As Uday Bhaskar, former Director-General of the Pharmaceuticals Export Promotion Council of India (Pharmexcil) and currently DG of the All-India Drug Control Officers&#8217; Confederation, put it in reporting by Mint: <em>&ldquo;In some states, there has been no recruitment for more than 12 years.&rdquo;<\/em><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What an inspector is legally empowered to do<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Enter and inspect premises where drugs are manufactured, stored or sold.<\/li>\n\n<li>Draw samples for analysis and route them to a government analyst.<\/li>\n\n<li>Examine records \u2014 batch manufacturing records, analytical worksheets, complaint files, distribution records.<\/li>\n\n<li>Seize stock and documents, and launch prosecution under the 1940 Act.<\/li>\n\n<li>Recommend suspension or cancellation of a manufacturing licence to the licensing authority.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f4cb; How the WHO Rotational Fellowship Was Set Up<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Geneva programme was not an Indian initiative announced unilaterally \u2014 it began with an invitation. According to Mint&#8217;s reporting, CDSCO initiated an internal selection process after the WHO Prequalification Unit (WHO-PQT) formally invited nominations for an inspector to join its Geneva team for &ldquo;a period of six months (less one day).&rdquo;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">WHO framed the scheme as capacity building for national regulatory authorities: <em>&ldquo;This country capacity building programme is specifically designed for regulators from priority member-states to enable them to expand their technical competencies through hands-on participation in prequalification activities.&rdquo;<\/em> Dr Yvan J.-F. Hutin, WHO representative to India, described it as a rotational fellowship whose fellows work directly with prequalification teams and carry the expertise back to national systems.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">WHOs own rationale, as reported: <em>&ldquo;This rotation represents a great opportunity for the candidate, the NRA, and the region for capacity development, especially hands-on experience in various regulatory functions and the working procedures of WHO-PQT.&rdquo;<\/em> The position is deliberately time-limited with no possibility of extension, so that a different national regulator can benefit each cycle.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">The selection pipeline, step by step<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">CDSCO issued an office memorandum on 9 November 2026 setting out eligibility. The sequence was:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Qualification gate<\/strong> \u2014 applicants must hold a postgraduate degree in pharmacy or science.<\/li>\n\n<li><strong>Mandatory e-learning<\/strong> \u2014 all 13 training modules on the SAKSHAM portal, the health ministry&#8217;s digital learning platform, completed by 31 October 2026.<\/li>\n\n<li><strong>Written examination<\/strong> \u2014 100 multiple-choice questions in 90 minutes, conducted by the top drug regulator.<\/li>\n\n<li><strong>Interview<\/strong> \u2014 held on 12 November 2026 at CDSCO headquarters in New Delhi and across zonal offices.<\/li>\n\n<li><strong>Deployment<\/strong> \u2014 regulators from CDSCO are expected to visit WHO headquarters on a rotational basis for about six months, with postings beginning 16 February 2027.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Three officials were selected for the current exercise. A senior official familiar with the matter described the gap being addressed in terms buyers will recognise: <em>&ldquo;The key area where India needs to upgrade itself is improving the scrutiny of practices, thorough document reviews and inspections in line with global benchmarks.&rdquo;<\/em> The same official noted that a comparable review was last conducted before the COVID-19 pandemic \u2014 more than five years earlier.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f3ed; What Pre-Qualification Scrutiny Actually Checks<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The significance of the fellowship is not the travel. It is exposure to how WHO-PQT evaluates a product and its manufacturing site before granting prequalification \u2014 an evaluation that many procurement agencies in low- and middle-income countries treat as a purchasing prerequisite.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">WHO prequalification assessment broadly runs across four layers, each of which a fellow would work on directly:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Product dossier review<\/strong> \u2014 chemistry, manufacturing and controls data, stability data, and bioequivalence evidence for interchangeable products.<\/li>\n\n<li><strong>Site inspection<\/strong> \u2014 a WHO-conducted or WHO-accepted GMP inspection of the manufacturing site and, where relevant, the contract research organisation that ran the bioequivalence study.<\/li>\n\n<li><strong>Programme-level compliance<\/strong> \u2014 ongoing testing, variation management, and responses to complaints or field alerts after prequalification is granted.<\/li>\n\n<li><strong>Comparator and reference-product integrity<\/strong> \u2014 for multisource products, the identity and selection of the comparator used in bioequivalence studies.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">For an Indian manufacturer, the operational consequence is that WHO-GMP certificates issued under the state licensing system are a starting point, not an equivalence. A certificate evidences that a facility was inspected against defined standards on a given date. It does not, by itself, evidence that a specific product dossier has been assessed or that post-marketing obligations are being met.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f50d; How Buyers Should Read Inspection-Derived Documents<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Given that inspection capacity is uneven across states and that inspector training is only now being benchmarked internationally, buyers should weight documents by how directly they reflect an independent assessment rather than an administrative one.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Document hierarchy, strongest first<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>WHO prequalification listing<\/strong> \u2014 the product-level outcome of an independent dossier review plus site inspection. The strongest single signal available for multisource medicines.<\/li>\n\n<li><strong>Regulatory-agency approvals from stringent authorities<\/strong> \u2014 US FDA approval or an EU GMP certificate from an EEA authority, both of which involve their own inspectorates arriving on-site.<\/li>\n\n<li><strong>Certificate of Pharmaceutical Product (COPP)<\/strong> \u2014 a government-to-government attestation in the WHO format. Useful, but it certifies that the product is licensed and the site inspected for the stated scope; it is an administrative document, not a finding of product-specific quality.<\/li>\n\n<li><strong>WHO-GMP certificate issued by a state authority<\/strong> \u2014 confirms a facility inspection against WHO-GMP standards within the scope listed. Necessary, not sufficient.<\/li>\n\n<li><strong>Manufacturing licence and product permission<\/strong> \u2014 the legal minimum. Confirms the right to manufacture, nothing about compliance performance.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">The practical check is not whether the strongest document exists, but whether the documents agree with each other. A common red flag is a WHO-GMP certificate whose listed dosage forms or premises address do not match the product being offered, or a COPP that names a different manufacturing site than the one on the batch record.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Questions that reveal inspection depth<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Which authority inspected the site, and on what date? A certificate with no inspection date is a photocopy, not a record.<\/li>\n\n<li>Was the inspection announced or unannounced? Unannounced inspections are far harder to prepare for.<\/li>\n\n<li>Does the certificate scope cover the exact dosage form and the exact strength you are importing?<\/li>\n\n<li>Which state administration issued it, and has that administration been subject to any noted capacity constraints or recruitment freeze?<\/li>\n\n<li>Has the facility been inspected for this product under a prequalification or stringent-authority programme, or only for licensing?<\/li>\n\n<li>Are there objections, show-cause notices or suspension recommendations reported against this site in the last 24 months?<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">&#x26a0;&#xfe0f; Five Pitfalls When Relying on Indian Inspection Documents<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Treating a WHO-GMP certificate as a product approval.<\/strong> It is a site-and-scope certificate. It says nothing about whether a specific finished product&#8217;s dossier was assessed.<\/li>\n\n<li><strong>Ignoring the issuing state.<\/strong> State administrations differ in inspection frequency and specialist capacity. The same certificate format carries different evidentiary weight.<\/li>\n\n<li><strong>Missing the expiry or review date.<\/strong> GMP certificates are time-bound. An expired certificate attached to a current quotation is a documentation failure even if the facility is genuinely compliant.<\/li>\n\n<li><strong>Accepting a certificate that names a sister unit.<\/strong> Group companies routinely circulate the strongest group certificate. Verify the premises address against the batch record.<\/li>\n\n<li><strong>Over-reading a favourable inspection.<\/strong> An inspection is a point-in-time finding. Continuous compliance is evidenced by complaint trends, recall history and repeat inspection outcomes.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f52e; Why the Fellowship Matters Beyond the Inspectorate<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Industry reaction has been cautiously positive. Viranchi Shah, national spokesperson of the Indian Drug Manufacturers&#8217; Association, told Mint that regulations change as science develops and warrant upgrades in approach: <em>&ldquo;While half of our exports go to Europe and the US, the other half goes to countries using WHO-GMP as their regulatory expectation.&rdquo;<\/em> He described the programme as a platform to exchange information and to put India&#8217;s point of view forward.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The backdrop is reputational as much as technical. Mint&#8217;s reporting ties the move to India&#8217;s effort to address quality-scrutiny gaps and allay apprehensions about the quality of drugs manufactured in the country, referencing suspected contamination of Indian-made cough syrups in The Gambia and Uzbekistan in 2022. India&#8217;s pharmaceutical market is widely described as the pharmacy of the world, valued at around USD 60 billion in the same reporting.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Three structural consequences are worth tracking for buyers planning procurement into 2027 and beyond:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Expect higher documentation standards.<\/strong> If CDSCO inspectors return from WHO-PQT with familiarity with dossier-level scrutiny, the practical bar for the records Indian manufacturers keep will rise to meet it.<\/li>\n\n<li><strong>Expect converging inspection language.<\/strong> Exposure to WHO-PQT working procedures tends to harmonise how inspection findings are written, which makes cross-country comparison of Indian inspection records easier for buyers.<\/li>\n\n<li><strong>Do not expect immediate capacity relief.<\/strong> Three officers on six-month rotations is a training investment, not a staffing increase. The state-level recruitment gap Bhaskar describes is a fiscal and administrative question that a fellowship programme does not answer.<\/li>\n<\/ol>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">&#x2705; Practical Checklist for Buyers<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Use this before placing an order with an Indian manufacturer, particularly where the sourcing decision rests on regulatory documentation rather than a prior commercial relationship:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>&#x2705; Confirm the manufacturing licence number, issuing state authority, and current validity.<\/li>\n\n<li>&#x2705; Confirm the WHO-GMP certificate is in date, and note the inspection date it rests on.<\/li>\n\n<li>&#x2705; Match the certificate&#8217;s listed dosage forms and premises address against the product and batch record.<\/li>\n\n<li>&#x2705; Check whether the product itself carries a WHO prequalification listing, not just the site&#8217;s certificate.<\/li>\n\n<li>&#x2705; Ask whether the site has been inspected by a stringent authority, and request the outcome date.<\/li>\n\n<li>&#x2705; Request the COPP and verify the manufacturing site named on it matches the batch record.<\/li>\n\n<li>&#x2705; Ask for recall and complaint history over the last 24 months, in writing.<\/li>\n\n<li>&#x2705; Verify the exporter or distributor is a licensed entity you can trace, not only an email address.<\/li>\n\n<li>&#x2705; Retain the full document set with dates, so a later discrepancy is traceable to its source.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>, which is maintained by the Indian Medical Supplies and Distributors Association.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">&#x2753; Frequently Asked Questions<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Are all Indian drug inspectors employed by CDSCO?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. The large majority of manufacturing inspections are carried out by State Drug Control Administrations under the Drugs and Cosmetics Act, 1940 and Rules, 1945. CDSCO, headed by the DCGI, handles central functions \u2014 new drug approvals, clinical trials, import registration \u2014 and coordinates joint inspections. Staffing and recruitment therefore vary by state rather than nationally.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Does a WHO rotational fellowship change a manufacturer&#8217;s certification status?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. It is a training programme for individual regulators. It does not alter any facility&#8217;s licence, GMP certificate or prequalification status. Its effect is indirect \u2014 on the technical standard of future Indian inspections and on how inspection findings are documented.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Is a WHO-GMP certificate the same as WHO prequalification?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No, and the distinction matters commercially. A WHO-GMP certificate is issued by a national or state authority confirming a site was inspected against WHO-GMP standards. WHO prequalification is a WHO assessment of a specific product&#8217;s dossier together with its manufacturing site, and it is product-level rather than site-level.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Why does the issuing state matter to an international buyer?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Because inspection capacity is uneven. Manufacturing inspections sit with state administrations that differ in resources and staffing \u2014 reporting has noted recruitment gaps of more than a decade in some states, and the Confederation of drug control officers has publicly flagged limited resources. The statutory standard is national; the inspection intensity is not.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The source material for the WHO fellowship details, selection timeline and quotes in this guide comes from reporting by Mint (16 November 2026, Priyanka Sharma) and DrugsControl Media Services (17 November 2026). Regulatory roles and statutory powers described above follow the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\">For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Every certificate of WHO-GMP compliance, every import registration, and every not of standard quality alert that an international buyer relies on is produced by a human being: a drug inspector. The strength of India&#8217;s regulatory paperwork is therefore capped by the strength of its inspection workforce. In November 2026, that workforce came into focus with [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[42,48,29,49,44],"class_list":["post-3738","post","type-post","status-publish","format-standard","hentry","category-knowledge","tag-cdsco","tag-generic-medicines","tag-india-pharmacy","tag-indian-pharma","tag-who","entry"],"_links":{"self":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3738"}],"version-history":[{"count":0,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3738\/revisions"}],"wp:attachment":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}